RecruitingNot ApplicableNCT06609148

Probiotic in Patients With Bile Acid Malabsorption/Diarrhea

Randomized, Double-Blind, Placebo-Controlled Trial of De Simone Formulation Probiotic in Patients With Bile Acid Malabsorption/Diarrhea Unassociated With Ileal Resection


Sponsor

Mayo Clinic

Enrollment

24 participants

Start Date

Jan 2, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

The purpose of this study is to assess effect of the DSF probiotic on fecal bile acid levels in patients with BAM.


Eligibility

Min Age: 18 Years

Inclusion Criteria12

  • Prior diagnosis of bile acid malabsorption documented in the medical history based on
  • either serum C4 \>52.5ng/mL, or
  • fecal 48h total BA excretion \>2337 μmol/48h, or
  • primary BA \>5% 48h stool collection or \>10% in single stool sample.
  • For women of childbearing potential
  • A negative urine pregnancy test prior to dispensing the study product
  • Agreement to comply with approved methods of contraception during the whole study: unless they meet the criteria of post-menopausal, i.e. 12 months of spontaneous amenorrhea, women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, including women whose career, lifestyle, or sexual orientation precludes intercourse with a male partner, should use one or more of the following acceptable methods of contraception that should be maintained throughout the study:
  • Surgical sterilization
  • Hormonal contraception (implantable, patch, oral, intra-muscular)
  • Intra-uterine device
  • Double barrier method (diaphragm plus condom)
  • At the discretion of the investigator, total abstinence is acceptable in cases where age, career, lifestyle, or sexual orientation of the patient ensures compliance

Exclusion Criteria8

  • Use of oral antibiotics and probiotics within the last 4 weeks.
  • Pregnancy or lactation.
  • Concomitant use of bile acid sequestrants, must stop 10 days before starting 7-day stool dairy and for the duration of the study.
  • History of ileal resection.
  • Diabetes mellitus (type 1)
  • BMI ≥ 40 kg/m\^2
  • Diagnosis of gastrointestinal diseases that are associated with inflammation such as inflammatory bowel diseases and celiac diseases or gastrointestinal infection in the prior 4 weeks
  • Any condition or personal circumstance that, in the opinion of the investigator, renders the subject unlikely or unable to comply with the full study protocol or could interfere with the study assessments

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIETARY_SUPPLEMENTDe Simone formulation probiotic

Subjects will be given De Simone formulation probiotic 900 billion CFU, 3 times per day for 21-24 days

DIETARY_SUPPLEMENTPlacebo

Subjects will be given a placebo for 21-24 days


Locations(1)

Mayo Clinic in Rochester

Rochester, Minnesota, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06609148


Related Trials